Abstract

Radiation therapy remains an important component of cancer treatment. Gene-encoded proteins were the actual executors of cellular functions. Proteomic was a novel technology that can systematically analysis protein composition and measure their levels of change, this was a high throughput method, and were the import tools in the post genomic era. In recent years, rapid progress of proteomic have been made in the study of cancer mechanism, diagnosis, and treatment. This article elaborates current advances and future directions of proteomics in the discovery of radiosensitive cancer biomarkers.

Highlights

  • Radiation therapy is a highly targeted treatment accurately suppressing the tumor with wide ranging application, and contributed to approximately 40% of all cancer cures across the world [1]

  • Wu et al analyzed the proteomic changes of tumor tissues before and after radiation therapy in patients of nasopharyngeal carcinoma and found that endoplasmic reticulum protein 29 (ERP29), manganese superoxide dismutase (Mn-SOD), heat shock protein 27 (HSP27), and glutathione S-transferase (GST) were significantly upregulated and correlated with radiation resistance; ERp29 was significantly overexpressed in radiationresistant tumor tissues as verified by immunohistochemistry; the application of small RNA silencing technique to downregulate ERP29 expression enhanced both radiosensitivity and apoptosis in CNE-1 and 6-10B cells [40]

  • Guo et al analyzed the protein kinase profiles of MCF-7 cell line and its cognate radiation-resistant cell line MCF-7/C6 and validated the results showed that checkpoint kinase 1 (CHK1), cell cycle protein-dependent kinases 1 and 2 (CDK1 and CDK2) were significantly upregulated in the radiation resistant cell lines; this suggests that both DNA repair and cell cycle were involved in regulating breast cancer radiation resistance [69]

Read more

Summary

INTRODUCTION

Radiation therapy is a highly targeted treatment accurately suppressing the tumor with wide ranging application, and contributed to approximately 40% of all cancer cures across the world [1]. Proteomic was an advanced systemic biology research method in the “post-genomic” era, it was studied by large-scale screening and identification of protein expression in body fluids, tissues, cells or organisms under various conditions, and protein-protein interactions will be well recognized [13]. Researchers attempt to analyze protein expression in tumor tissue and plasma during radiation therapy by proteomics technology, this will be facilitating the detection of proteins that play a key role during the course of radiotherapy and biomarkers that can predict radiotherapy sensitivity in the earlier phase [21, 22]. We reviewed the research progress of proteomics in screening tumor radiotherapy sensitivity markers (Figure 1)

Matrix-Assisted Laser Desorption/ Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS)
Isobaric Tags for Relative and Absolute Quantification (iTRAQ)
Liquid Chromatography With Tandem Mass Spectrometry (LC-MS/MS)
Multiple Reaction Monitoring (MRM)
Sequential Window Acquisition of All Theoretical Mass Spectra (SWATH-MS)
RADIOSENSITIVITY BIOMARKERS IN CANCERS
Head and Neck Cancers
Nasopharyngeal Carcinoma
Other Types of Head and Neck Cancers
Thoracic Cancers
Esophageal Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Abdominopelvic Tumors
Rectal Cancer
Prostate Cancer
Extracranial Tumors in Children
CHALLENGES OF PROTEOMICS
Findings
SUMMARY AND PERSPECTIVE

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.